| Filed On | Filing |
|---|---|
| 27 Oct 2026 | 10-Q |
| 27 Oct 2026 |
8-K: Results of Operations and Financial Condition
(Former name or former address, if changed since last report) |
| 16 Oct 2026 |
Form 4: Hopman Mark, Chief Commercial Officer
Sold 775 shares ($13.4K) |
| 07 Oct 2026 | SCHEDULE 13G |
| 05 Oct 2026 |
Form 4: Hopman Mark, Chief Commercial Officer
Sold 370 shares ($7.02K) |
| 01 Oct 2026 | 144 |
| 23 Sep 2026 |
Form 4: Jones Christy, Director
Sold 6,430 shares ($148K) |
| 22 Sep 2026 | 144 |
| 18 Sep 2026 |
Form 4/A: Hopman Mark, Chief Commercial Officer
Sold 35,994 shares ($665K) |
| 17 Sep 2026 |
Form 4: Mensinger Mike, Chief Product Officer
Sold 2,650 shares ($58.3K) |
| 17 Sep 2026 |
Form 4: Hopman Mark, Chief Commercial Officer
Sold 30,779 shares ($620K) |
| 17 Sep 2026 | 424B5 |
| 17 Sep 2026 |
8-K: Other Events
IRVINE, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) – Beta Bionics, Inc. (Nasdaq: BBNX) today announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, $125.0 million of share... |
| 16 Sep 2026 | 144 |
| 16 Sep 2026 | 144 |
| 16 Sep 2026 | FWP |
| 16 Sep 2026 | 424B5 |
| 15 Sep 2026 |
Form 4: Hopman Mark, Chief Commercial Officer
Sold 775 shares ($12K) |
| 15 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking s... |
| 10 Sep 2026 |
Form 4: Hopman Mark, Chief Commercial Officer
Sold 36,870 shares ($681K) |
Loading...
